Canertinib (CI-1033)

Canertinib (CI-1033) は有効的に チロシンキナーゼを抑制で、 EGFR と erbB2 を作用する時IC50 はそれぞれ 1.5 nM と 9.0 nMになる.

目録号S1019
5 5 7レビュー 4製品表彰状
価格 在庫  
USD 88 In stock
USD 214 In stock
USD 340 In stock
USD 844 In stock

Canertinib (CI-1033) 化学構造
分子量: 485.94

品質と確認

カスタマーレビュー(7)

Quality Control & MSDS

製品情報

製品の説明

生物活性

情報 Canertinib (CI-1033) は有効的に チロシンキナーゼを抑制で、 EGFR と erbB2 を作用する時IC50 はそれぞれ 1.5 nM と 9.0 nMになる.
目標 EGFR ErbB2
IC50 1.5 nM 9.0 nM [1]
In vitro試験 CI-1033 shows excellent potency for irreversible inhibition of erbB2 autophosphorylation in MDA-MB 453 cells. CI-1033 also shows high permeability in Caco-2 cells and inhibits secretory transport of vinblastine, which indicates that CI-1033 is a likely inhibitor of the P-gp. [1] CI-1033 alone, significantly suppresses constitutively activated Akt and MAP kinase. In combination with gemcitabine, CI-1033 inhibits Akt and prevents increased levels of MAPK phosphorylation. CI-1033 stimulates p27 expression and p38 phosphorylation in MDA-MB-453 cells. [2] CI-1033 is highly specific to the erbB receptor family and not sensitive to PGFR, FGFR or IR even at 50 μM. CI-1033 shows high levels of inhibition in A431 cells expressing EGFR with IC50 of 7.4 nM. CI-1033 suppresses heregulin-stimulated tyrosine phosphorylation of erbB2, erbB3 and erbB4 with IC50 of 5, 14 and 10 nM, respectively. CI-1033 also inhibits expression of pp62c-fos in response to heregulin. [3] CI-1033 is predicted to modify Cys773 covalently within the ATP binding site of the HER2 kinase and enhances destruction of both mature and immature ErbB-2 molecules. [4] CI-1033 induces a significant decrease in measurable phosphorylation of tyrosine residues 845 and 1068 of EGFR, which are responsible for Src and Ras/MAPK signaling respectively. The corresponding residues of Her-2, tyrosine residues 877 and 1248 are dephosphorylated significantly by CI-1033 at a concentration of 3 μM or higher. CI could block EGFR internalization and increase the rate of apoptosis in primary osteosarcoma cells in a titratable fashion. [5] In addition, CI-1033 inhibits the proliferation of TT, TE2, TE6 and TE10 cells significantly at 0.1 nM. [6]
In vivo試験 CI-1033 shows impressive activity against A431 xenografts in nude mice at 5 mg/kg of body weight. [1] CI-1033 (20 to 80 mg/kg/d) achieves a high degree of tumor regressions in H125 xenograft models. [3] Oral administration of CI-1033 causes a marked inhibition of growth in TT, TE6 and TE10 xenografts in nude mice, without animal death and <10% weight loss. [6]
臨床試験 Phase II trials have been completed in patients with metastatic breast cancer.
特集 First kinase inhibitor to show irreversible activity and to have entered clinical trials (serving as a template for further development).

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

Tyrosine Kinase Assays Enzyme assays for determination of IC50 are performed in 96-well filter plates in a total volume of 0.1 mL, containing 20 mM Hepes, pH 7.4, 50 mM sodium vanadate, 40 mM magnesium chloride, 10 μM adenosine triphosphate (ATP) containing 0.5 mCi of [32P]ATP, 20 mg of polyglutamic acid/tyrosine, 10 ng of EGFR tyrosine kinase, and appropriate dilutions of CI-1033. All components except the ATP are added to the well and the plate is incubated with shaking for 10 min at 25 °C. The reaction is started by adding [32P]ATP, and the plate is incubated at 25 °C for another 10 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid (TCA). The plate is kept at 4 °C for at least 15 min to allow the substrate to precipitate. The wells are then washed five times with 0.2 mL of 10% TCA and 32P incorporation determined with a Wallac β plate counter.

細胞アッセイ: [6]

細胞系 TT, TE2, TE6 and TE10 cells
濃度 0.1-5.0 nM
処理時間 1, 3, 5 and 7 days
方法 Cells (1 × 104) are seeded in each well of a 24-well plastic culture plate and left overnight in DMEM or RPMI-1640 supplemented with 10% FBS. The next morning, the cells are treated with the indicated concentrations of CI-1033 (0.1-5.0 nM) for varying periods (1, 3, 5 and 7 days). After treatment, the cells are counted using a Coulter counter. The percent of cell proliferation is calculated by this formula: treatment cell number/control cell number × 100 for each time period.

動物実験: [1]

動物モデル A431 xenografts established in nude mice
製剤 In solution as the isethionate salts
投薬量 ~18 mg/kg
管理 Administered orally
1

参考

化学情報

Download Canertinib (CI-1033) SDF
分子量 485.94
化学式

C24H25ClFN5O3

CAS No. 267243-28-7
別名 PD-183805
溶解度 (25°C)
  • DMSO 2 mg/mL
  • 水 <1 mg/mL
  • エタノール 9 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名 N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide

研究分野

カスタマーレビュー (7)


Click to enlarge
Rating
Source Cell Cycle 8, 13, 2050-2056. Canertinib (CI-1033) purchased from Selleck
Method Western Blot
Cell Lines H1993 cells
Concentrations 1.5 uM
Incubation Time 4 h
Results We pretreated the cells with SU11274 for 48 h before adding, for the final 4 h, the PKC δ inhibitor rottlerin, GO6976 (an inhibitor blocking the activities of classical PKCs only), or CI-1033 (an irreversible ErbB TKI). Inclusion of rottlerin for the final 4 h effectively inhibited the re-activation of Akt, ErbB2 and ErbB3 (Fig. 4B). GO6976 was ineffective, while CI-1033 had an intermediate impact on the restoration of ErbB/AKT signaling.

Click to enlarge
Rating
Source Cell Cycle 8, 13, 2050-2056. Canertinib (CI-1033) purchased from Selleck
Method Cell proliferation assay
Cell Lines H1993 cells
Concentrations 1.5uM
Incubation Time 6 d
Results After up to 6 days of incubation, SU11274 alone only moderately inhibited H1993 cell growth, while the combination of SU121274 and CI-1033 was much more effective. Surprisingly, treatment with CI-1033 alone had no impact on cell growth.

Click to enlarge
Rating
Source Canertinib (CI-1033) purchased from Selleck
Method Western Blotting
Cell Lines A431 cells
Concentrations 10nM
Incubation Time 30mins
Results Conclusion-P-EGFR (Tyr845) signal is inhibited in varying degree with EGF stimulation, and is not detectable without EGF stimulation. Inhibition results in table below right

Click to enlarge
Rating
Source Dr. Kian Kani of Cedars-Sinai Medical Center. Canertinib (CI-1033) purchased from Selleck
Method Western blot
Cell Lines H1975 cells
Concentrations 10-300 nM
Incubation Time 2 h
Results CI-1033 treatment resulted in a reduction of EGFR phosphorylation in H1975 cells.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Canertinib (CI-1033) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-0.05 nM
Incubation Time 3 h
Results CI-1033 treatment resulted in a reduction of EGFR phosphorylation in Breast cancer cells.

Click to enlarge
Rating
Source Carcinogenes, 2010, 31, 1948–1955 . Canertinib (CI-1033) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas CI-1033 and other inhibitors tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells).

Click to enlarge
Rating
Source Carcinogenesis, 2010, 31, 1948–1955. Canertinib (CI-1033) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Lapatinib, LY294002 and Bortezomib significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells.

製品表彰状 (4)

  • Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. [Vivanco I, et al. Cancer Discov 2012;2(5):458-71]

    PubMed: 22588883
  • The fibroblast-derived paracrine factor neuregulin-1 has a novel role in regulating the constitutive color and melanocyte function in human skin. [Choi W, et al. J Cell Sci 2010;123(Pt 18):3102-11]

    PubMed: 20736300
  • Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. [Dong Z, et al. Carcinogenesis 2010;31(11):1948-55]

    PubMed: 20837598
  • Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. [Wang S, et al. Cell Cycle 2009;8(13):2050-6]

    PubMed: 19502802

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related EGFR 阻害剤

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992)は不可逆的にEGF受容体/ HER2含むEGF受容体を抑制、 EGFR L858R , EGFR L858R/T790M と HER2を作用すると、 IC50がそれぞれ0.5 nM, 0.4 nM, 10 nM, 14 nMとなる。

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744)は、2nMのIC50によるHER1/EGFR阻害剤です。

  • Gefitinib (ZD1839)

    Gefitinib (ZD1839) は、NR6wtEGFRとNR6W細胞のTyr1173、Tyr992、Tyr1173とTyr992のためのEGFR阻害剤で、IC50 がそれぞれ 37 nM、 37nM、 26 nM 、57 nMです。

  • Lapatinib (GW-572016) Ditosylate

    Lapatinib (GW-572016) Ditosylateは有効EGFRとErbB2阻害剤、IC50それぞれ10.8と9.2nM。

  • AC480 (BMS-599626)

    AC480 (BMS-599626)は、HER1とHER2の選択的で口で有効な阻害剤で、IC50 がそれぞれ 20 nM と 30 nMです。

  • PD153035 HCl

    PD153035 HClは、EGFRの強力で特定の阻害剤で、Ki と IC50 がそれぞれ 5.2 pM と 29 pMです。

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42)は、EGFRの選択的な阻害剤、ErbB2とJAK2で、IC50 がそれぞれ 0.1 μM、 13.5 μM、 and ~10 μMです。

  • CP-724714

    CP-724714は、10nMのIC50によるerbB2の強力な、選択的な阻害剤です。

  • WZ3146

    WZ3146は、EGFR(L858R)とEGFR(E746_A750)の変異体選択元に戻らない阻害剤で、IC50 がそれぞれ 2 nM と 2 nMです。

  • WZ4002

    WZ4002は、EGFR L858RとEGFR L858R/T790Mのための新しい、変異体選択EGFRキナーゼ阻害剤で、 IC50 がそれぞれ 2 nM と 8 nMになる。

最近見られたアイテム

Tags: Canertinib (CI-1033)を買う | Canertinib (CI-1033)供給者 | Canertinib (CI-1033)を購入する | Canertinib (CI-1033)費用 | Canertinib (CI-1033)生産者 | オーダーCanertinib (CI-1033) | Canertinib (CI-1033)代理店
お問い合わせ